Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer.

about

Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer.

Item

http://www.wikidata.org/entity/Q47813594

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer.

@en

Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer.

@nl

type

Item

label

Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer.

@en

Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer.

@nl

prefLabel

Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer.

@en

Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer.

@nl

P1476

Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer.

@en

P2093

Jack Patrick Gleeson

http://www.w3.org/2001/XMLSchema#string

Niamh M Keegan

http://www.w3.org/2001/XMLSchema#string

Patrick G Morris

http://www.w3.org/2001/XMLSchema#string

P2860

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

Twenty years of anti-HER2 therapy-associated cardiotoxicity

Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4

HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

P304

1-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14712598.2018.1410132

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29183167

http://www.w3.org/2001/XMLSchema#string